



## **CORE BRIEF TO MANAGEMENT GROUP MEMBERS**

### **MEETING HELD ON 18 JULY 2019**

This briefing sets out the key areas of discussion and decision. It aims to ensure the Management Group members have a common core brief to disseminate within their organisation.

#### **1. Welcome and Introductions**

The Chair welcomed members to the meeting.

#### **2. Genomics for Precision Medicine Strategy Wales**

Dr Catrin Middleton, Programme Director, delivered a presentation on the strategy and progress to date in establishing a Programme Office and Genomics Partnership Wales.

#### **3. Lynch Syndrome Testing**

Members received a paper that outlined the implementation plan and confirmed the funding requirement for the introduction of Lynch Syndrome testing for all patients with colorectal cancer.

It was noted that only ABUHB had included funding within its current IMTP. Clarification was required on cost comparison to existing testing. Members expressed the view that clarification was required regarding the governance of the NHS Wales Health Collaborative Executive Group taking a decision on this service, and other similar matters, outside of the WHSSC Joint Committee and the ICP/IMTP planning process.

Members noted (1) that the funding for implementation of Lynch Syndrome testing for all patients in Wales with colorectal cancer was agreed by NHS Wales Health Collaborative Executive Group in January 2019; (2) the funding requirement for each health board; and (3) the implementation plan for Lynch Syndrome testing for all patients with colorectal cancer in Wales; and supported the case being taken to Joint Committee for final approval.

#### **4. Hereditary Anaemias**

Members received a paper that provided information on services currently available for patients in Wales with hereditary anaemias, the work which has been carried out to date to address gaps in the service and to notify members of the intention to develop a proposal for consideration in the 2020/21 ICP. It was noted that there was Ministerial interest in addressing the gaps in this service.

It was also noted that the gap analysis covered virtually all hereditary anaemias. It was agreed to explore the option of commissioning a service from Bristol (and Liverpool) further, given current developments in the way this service is being delivered in England, the relatively small number of patients in Wales and their geographic distribution.

Members noted (1) the information presented within the report; and (2) the development of a proposal for consideration in the 2020/21 ICP.

## **5. Minutes of the Previous Meeting and Action Log**

The minutes of the meeting held on 27 June 2019 were approved subject to a typographic correction.

Members noted the action log and received updates on:

- MG149 Cystic Fibrosis: IV Service: Transformation Fund – This had been raised at a meeting with WG earlier in the week. Carried forward.
- MG155 Financial Performance Report: EASC re-basing – SD confirmed that EASC had not been re-based.

## **6. Report from the Managing Director**

Members received the Managing Director's report, which included:

- **Vulnerable Persons Resettlement Scheme** At the request of the VPRS team in the DH the WHSS Patient Care team is supporting the Scheme with a particular focus on providing advice to the Home Office on placing complex cases with the most appropriate local authorities for their health care needs. WHSSC will also assist health boards to claim the maximum amount of financial support available for such cases.
- **Forensic Adolescent Consultation and Treatment Service** Arising out of the work of the FACTS strategy group the WHSS Team is conducting a review of the most appropriate commissioning model for this service which is currently commissioned by both WHSSC and WG. This work is supported by WG and the host health board (CTMUHB).

## **7. Major Trauma Operational Delivery Network (MTODN) Structure and Major Trauma Centre (MTC) Outline Business Case**

Members received papers that set out the proposed structure for the MTODN and its anticipated funding structure, and the outline business case for the MTC, together with information regarding a request for pre go live funding. Members also received a presentation on the feedback received from the recently completed Gateway Review.

It was agreed that the Implementation Board's response to the Gateway Review would influence the need for pre go live funding and that further scrutiny of the outline business case was required before Management Group members could make definitive recommendations to Joint Committee; however it was suggested that Joint Committee could be

asked to agree principles related to pre go live funding of critical posts, also that an approach could be made to WG to support such funding which was not included in the current ICP.

## **8. WHSSC Policy Group Update**

Members received a paper on the work of the WHSSC Policy Group and noted the information presented within the report. Particular reference was made to:

- Specialised Services Commissioning Policy CP164 Clinical trials; and
- Developing WHSSC Policies: Process and methods

## **9. Annual Self-Assessment**

Members received a paper that set out a series of prompts to aid the self-assessment exercise regarding the performance of the Group and its members. Members were invited to send their feedback to the Committee Secretary and Corporate Governance Officer by email.

## **10. Integrated Performance Report**

Members received an oral summary of the performance of services commissioned by WHSSC for May 2019 and noted the services in escalation and actions being undertaken to address areas of non-compliance.

## **11. Finance Report 2019-20 Month 3**

Members received a report that set out the financial position for WHSSC for the third month of 2019-20, being an under spend of £588k after release of structural provisions and forecast underspend of £2,832k for the full year.

